Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
AGIO Quote, Financials, Valuation and Earnings
Last price:
$29.19
Seasonality move
:
6.83%
Day range:
$27.10 - $30.04
52-week range:
$22.24 - $46.00
Dividend yield:
0%
P/E ratio:
3.91x
P/S ratio:
37.58x
P/B ratio:
1.33x
Volume:
915.7K
Avg. volume:
2.4M
1-year change:
-14.68%
Market cap:
$1.7B
Revenue:
$36.5M
EPS (TTM):
-$6.96
Analysts' Opinion
-
Consensus RatingAgios Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.25, Agios Pharmaceuticals, Inc. has an estimated upside of 30.64% from its current price of $29.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 31.47% downside risk from its current price of $29.17.
Fair Value
-
According to the consensus of 10 analysts, Agios Pharmaceuticals, Inc. has 30.64% upside to fair value with a price target of $35.25 per share.
AGIO vs. S&P 500
-
Over the past 5 trading days, Agios Pharmaceuticals, Inc. has underperformed the S&P 500 by -7.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Agios Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Agios Pharmaceuticals, Inc. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Agios Pharmaceuticals, Inc. reported revenues of $12.9M.
Earnings Growth
-
Agios Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Agios Pharmaceuticals, Inc. reported earnings per share of -$1.78.
Enterprise value:
525.6M
EV / Invested capital:
0.40x
Price / LTM sales:
37.58x
EV / EBIT:
--
EV / Revenue:
11.73x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-1.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$33.8M
Return On Assets:
-25.5%
Net Income Margin (TTM):
-895.86%
Return On Equity:
-27.53%
Return On Invested Capital:
-26.57%
Operating Margin:
-907.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $24M | $32.9M | $44.8M | $9M | $12.9M | |
| Gross Profit | $6.5M | $23.7M | $33.8M | $6.8M | $9.8M | |
| Operating Income | -$384.4M | -$407M | -$475.6M | -$102.8M | -$116.9M | |
| EBITDA | -$369.5M | -$401.3M | -$470.3M | -$101.5M | -$115.5M | |
| Diluted EPS | -$3.95 | $11.37 | -$6.96 | $16.22 | -$1.78 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $784.9M | $704.4M | $1.1B | $1B | |
| Total Assets | $1.5B | $1.2B | $1B | $1.8B | $1.4B | |
| Current Liabilities | $57.9M | $53.6M | $58.4M | $119.5M | $74.8M | |
| Total Liabilities | $146.7M | $130.2M | $120.4M | $165.1M | $101.4M | |
| Total Equity | $1.4B | $1.1B | $886.8M | $1.6B | $1.3B | |
| Total Debt | $99.1M | $75.6M | $60.8M | $44.5M | $26.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$289.7M | -$329.2M | -$409.9M | -$84.2M | -$88.2M | |
| Cash From Investing | $227M | $508.1M | $238M | $250.8M | $95.6M | |
| Cash From Financing | $4.6M | $10.4M | $11M | $2.6M | $4.4M | |
| Free Cash Flow | -$290.6M | -$330.1M | -$414.1M | -$84.6M | -$89.7M | |
AGIO
Sector
Market Cap
$1.7B
$28.1M
Price % of 52-Week High
63.45%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.49%
1-Year Price Total Return
-30.44%
-17.13%
Beta (5-Year)
0.867
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$26.12
200-day SMA
Sell
Level
$34.33
Bollinger Bands (100)
Sell
Level
30.41 - 42.39
Chaikin Money Flow
Buy
Level
25.3M
20-day SMA
Buy
Level
$27.13
Relative Strength Index (RSI14)
Buy
Level
50.66
ADX Line
Buy
Level
32.18
Williams %R
Buy
Level
-90.3262
50-day SMA
Sell
Level
$34.84
MACD (12, 26)
Sell
Level
-2.31
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
63.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.9085)
Buy
CA Score
(Annual)
Level (-0.0739)
Sell
Beneish M-Score
(Annual)
Level (0.8478)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-15.7244)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, AGIO has received 7 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AGIO average analyst price target in the past 3 months is $35.25.
-
Where Will Agios Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Agios Pharmaceuticals, Inc. share price will rise to $35.25 per share over the next 12 months.
-
What Do Analysts Say About Agios Pharmaceuticals, Inc.?
Analysts are divided on their view about Agios Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Agios Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Agios Pharmaceuticals, Inc.'s Price Target?
The price target for Agios Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $35.25 according to 10 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AGIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Agios Pharmaceuticals, Inc. is a Buy. 7 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AGIO?
You can purchase shares of Agios Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Agios Pharmaceuticals, Inc. shares.
-
What Is The Agios Pharmaceuticals, Inc. Share Price Today?
Agios Pharmaceuticals, Inc. was last trading at $29.19 per share. This represents the most recent stock quote for Agios Pharmaceuticals, Inc.. Yesterday, Agios Pharmaceuticals, Inc. closed at $29.17 per share.
-
How To Buy Agios Pharmaceuticals, Inc. Stock Online?
In order to purchase Agios Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AGIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AGIO
Sector
P/E ratio
3.91x
23.89x
PEG ratio
-0.10x
-0.01x
P/B ratio
1.33x
1.81x
Price / LTM sales
37.58x
1.59x
Growth Metrics
AGIO
Sector
Revenue growth
43.69%
4.62%
Earnings growth
-110.97%
11.06%
Revenue (5-year growth)
-20.91%
6.5%
Earnings forecast
-$1.90
-$0.21
Profitability
AGIO
Sector
Profitability FY 2024
$26.7M
$3.6M
Return on invested capital
-26.57%
-31.84%
Return on assets
-25.5%
-27.96%
Return on equity
-27.53%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Jan
29
Balance Sheet
AGIO
Sector
Total cash
$952.9M
$26.4M
Short term investments
$817.5M
$25.7M
Total assets
$1.7B
$76.9M
Long term debt
$26.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
